2024-09-25 - Analysis Report
## Regeneron Pharmaceuticals Inc (REGN) Stock Analysis Report

**1. Performance Comparison & Relative Strength:**

Regeneron Pharmaceuticals Inc (REGN) has a cumulative return of 96.25% compared to the S&P 500 (VOO) with a return of 133.37%. This indicates that REGN has underperformed the market by 37.12% in terms of cumulative return. The relative strength compared to the S&P 500 is currently at 37.89%, meaning that it is outperforming the market by 37.89% based on historical data.

**Regeneron Pharmaceuticals Inc** is a biotechnology company that develops and manufactures therapies for serious diseases. 

**2. Recent Price Movement:**

* **Closing price:** 1028.52
* **5-day moving average:** 1112.96
* **20-day moving average:** 1149.63
* **60-day moving average:** 1117.4

The stock is currently trading below all three moving averages, suggesting a potential downward trend. 

**3. Technical Indicators:**

* **RSI:** 22.76 (Indicates oversold conditions)
* **PPO:** -1.15 (Indicates weakness and potential for further decline)
* **Delta_Previous_Relative_Divergence:** -28.7 (Indicates recent short-term downtrend)
* **Expected Return:** 0.0% (The expected return over the next 5 years is currently 0%)

The RSI and PPO values suggest that the stock is currently in oversold territory and could be vulnerable to further decline. The negative Delta_Previous_Relative_Divergence further supports this observation. The expected return of 0% might indicate a cautious outlook on the stock's future performance.

**4. Recent Earnings & Outlook:**

| Date      | EPS   | Revenue |
|----------|-------|---------|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.70 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The most recent earnings report shows that Regeneron exceeded analyst expectations for both EPS and revenue.  Despite the strong performance, the stock has experienced a decline, likely due to broader market sentiment and concerns about the company's future growth prospects.

**5. News & Recent Issues:**

* **Recent Market Outlook:** Regeneron Pharmaceuticals' stock has been under pressure lately due to concerns about slowing growth, increased competition in the biotech sector, and potential pricing pressures. 
* **Analyst Opinions:**  Analysts have mixed opinions on Regeneron, with some expressing concerns about valuation and growth while others remain bullish based on the company's strong pipeline of potential drugs.
* **Performance Highlights:** Regeneron has historically been a strong performer, but recent performance has been sluggish. The company's future prospects are tied to the success of its existing drugs and its ability to develop new therapies.

**6.  Overall Analysis:**

Regeneron Pharmaceuticals (REGN) has been underperforming the market in recent months, with a negative relative strength and weak technical indicators suggesting potential for further decline. While the most recent earnings report exceeded expectations, concerns about growth and competition in the biotech sector have weighed on the stock. The company's future prospects are tied to its ability to deliver on its pipeline of new therapies.

**7. Conclusion:**

While REGN has a solid history and a strong portfolio of existing drugs, the current market sentiment and concerns about future growth prospects are creating a challenging environment for the stock. Investors should monitor the company's progress with its drug pipeline, upcoming earnings reports, and the broader market conditions before making any investment decisions. 
